Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.32 USD
Change Today +0.06 / 0.73%
Volume 252.3K
RGLS On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:58 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

regulus therapeutics inc (RGLS) Key Developments

Regulus Therapeutics Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-30-2015

Regulus Therapeutics Inc. Presents at BMO Capital Markets Biotech Corporate Access Day, Jul-30-2015 . Venue: Boston, Massachusetts, United States.

Regulus Therapeutics Inc. Initiates Phase I Clinical Study of RG-012

Regulus Therapeutics Inc. announced that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ('miR-21'). RG-012 is being developed by Regulus in a strategic alliance with Genzyme for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. The Phase I clinical study is being conducted in the United States as a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of subcutaneous dosing of RG-012 in healthy volunteers. In addition to the Phase I clinical study, Regulus is currently enrolling Alport syndrome patients in a natural history of disease study called ATHENA. With this study, which has thirteen clinical sites worldwide, Regulus aims to learn more about the changes in renal function over time in patients with Alport syndrome. Data from the ATHENA study will provide the clinical basis for the design of a Phase II study to monitor the therapeutic effect of RG-012 on the decline in renal function and time to end-stage renal disease in Alport syndrome patients. In addition, Regulus expects that many patients enrolled in ATHENA will be eligible to enroll in a Phase II proof-of-concept study, which Regulus expects to initiate under its 'Clinical Map Initiative' following the conclusion of the Phase I clinical study.

Regulus Therapeutics Inc. Announces Management Changes

Regulus Therapeutics Inc. announced that Kleanthis G. Xanthopoulos, Ph.D. has resigned as President and Chief Executive Officer and as a member of the company’s Board of Directors, effective June 1, 2015, to pursue investment opportunities in the biotechnology industry. Paul Grint, M.D., who previously served as Chief Medical Officer, has been appointed as President and Chief Executive Officer and as a member of Board of Directors effective June 1, 2015. In addition, Neil W. Gibson, Ph.D., who has served as Chief Scientific Officer, will continue through June 30, 2015 at the company as President's Fellow to assist Dr. Grint in assembling a new leadership team.

Regulus Therapeutics Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Regulus Therapeutics Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, revenues under strategic alliances and collaborations were $4,200,000 against $1,631,000 a year ago. Loss from operations was $12,871,000 against $10,705,000 a year ago. Loss before income taxes was $14,491,000 against $12,740,000 a year ago. Net loss was $14,487,000 against $12,741,000 a year ago. Basic and diluted net loss per share was $0.29 against $0.30 a year ago. Net loss in the first quarter 2015 included approximately $1.8 million in non-cash charges associated with amended and restated convertible promissory note compared to approximately $2.1 million in the same period in 2014. Revenue for the first quarter 2015 was highlighted by the achievement of a $2.5 million preclinical milestone upon AstraZeneca's selection of RG-125 as a clinical candidate.

Regulus Therapeutics Inc., Annual General Meeting, Jun 10, 2015

Regulus Therapeutics Inc., Annual General Meeting, Jun 10, 2015., at 09:00 Pacific Standard Time. Location: 3545 John Hopkins Court. Agenda: To elect the seven nominees for director named herein to serve until the next annual meeting and their successors are duly elected and qualified; to ratify the selection by the audit committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending 2015; and to conduct any other business properly brought before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGLS:US $8.32 USD +0.06

RGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.92 AUD +0.03
Enzon Pharmaceuticals Inc $1.38 USD 0.0001
Galena Biopharma Inc $1.64 USD -0.02
Silence Therapeutics PLC 278.00 GBp -2.37
View Industry Companies
 

Industry Analysis

RGLS

Industry Average

Valuation RGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.4x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGULUS THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.